Literature DB >> 32236882

Molecular Mechanism and Cannabinoid Pharmacology.

Lesley D Schurman1, Dai Lu2, Debra A Kendall3, Allyn C Howlett4, Aron H Lichtman5,6.   

Abstract

Since antiquity, Cannabis has provoked enormous intrigue for its potential medicinal properties as well as for its unique pharmacological effects. The elucidation of its major cannabinoid constituents, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), led to the synthesis of new cannabinoids (termed synthetic cannabinoids) to understand the mechanisms underlying the pharmacology of Cannabis. These pharmacological tools were instrumental in the ultimate discovery of the endogenous cannabinoid system, which consists of CB1 and CB2 cannabinoid receptors and endogenously produced ligands (endocannabinoids), which bind and activate both cannabinoid receptors. CB1 receptors mediate the cannabimimetic effects of THC and are highly expressed on presynaptic neurons in the nervous system, where they modulate neurotransmitter release. In contrast, CB2 receptors are primarily expressed on immune cells. The endocannabinoids are tightly regulated by biosynthetic and hydrolytic enzymes. Accordingly, the endocannabinoid system plays a modulatory role in many physiological processes, thereby generating many promising therapeutic targets. An unintended consequence of this research was the emergence of synthetic cannabinoids sold for human consumption to circumvent federal laws banning Cannabis use. Here, we describe research that led to the discovery of the endogenous cannabinoid system and show how knowledge of this system benefitted as well as unintentionally harmed human health.

Entities:  

Keywords:  Allosteric modulation; CB1/CB2 receptor; CBD; Cannabinoid; Cannabis Use Disorder; Endocannabinoid; Opioid-sparing effects; Phytocannabinoid; Synthetic cannabinoid; THC

Year:  2020        PMID: 32236882     DOI: 10.1007/164_2019_298

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  6 in total

1.  The Use of Cannabis for Medical Purposes in the Arab World.

Authors:  Bader H Shirah; Mohammed M Ahmed
Journal:  Med Cannabis Cannabinoids       Date:  2020-12-07

Review 2.  Endocannabinoids at the synapse and beyond: implications for neuropsychiatric disease pathophysiology and treatment.

Authors:  Andrew Scheyer; Farhana Yasmin; Saptarnab Naskar; Sachin Patel
Journal:  Neuropsychopharmacology       Date:  2022-09-13       Impact factor: 8.294

3.  Δ9-Tetrahydrocannabinol inhibits Hedgehog-dependent patterning during development.

Authors:  Hsiao-Fan Lo; Mingi Hong; Henrietta Szutorisz; Yasmin L Hurd; Robert S Krauss
Journal:  Development       Date:  2021-10-05       Impact factor: 6.862

Review 4.  Alternative pain management via endocannabinoids in the time of the opioid epidemic: Peripheral neuromodulation and pharmacological interventions.

Authors:  Ming Tatt Lee; Ken Mackie; Lih-Chu Chiou
Journal:  Br J Pharmacol       Date:  2021-12-07       Impact factor: 9.473

5.  The cannabinoid receptors system in horses: Tissue distribution and cellular identification in skin.

Authors:  Piotr Kupczyk; Marta Rykala; Pawel Serek; Aleksandra Pawlak; Bartosz Slowikowski; Marcin Holysz; Grzegorz Chodaczek; Jan P Madej; Piotr Ziolkowski; Artur Niedzwiedz
Journal:  J Vet Intern Med       Date:  2022-07-08       Impact factor: 3.175

6.  The Influence of CB2-Receptor Ligands on the Memory-Related Responses in Connection with Cholinergic Pathways in Mice in the Passive Avoidance Test.

Authors:  Marta Kruk-Slomka; Agnieszka Dzik; Grazyna Biala
Journal:  Molecules       Date:  2022-07-01       Impact factor: 4.927

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.